Brokerages Set uniQure N.V. (NASDAQ:QURE) PT at $60.82

Shares of uniQure N.V. (NASDAQ:QURE) have been assigned an average rating of “Moderate Buy” from the thirteen analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $60.8182.

Several research analysts have recently weighed in on the stock. Cantor Fitzgerald lifted their target price on shares of uniQure from $47.00 to $80.00 and gave the stock an “overweight” rating in a research report on Thursday, September 25th. The Goldman Sachs Group lowered their price objective on shares of uniQure from $56.00 to $38.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 4th. UBS Group set a $95.00 target price on uniQure in a report on Thursday, September 25th. Stifel Nicolaus lowered their price target on uniQure from $50.00 to $40.00 and set a “buy” rating on the stock in a report on Thursday, December 11th. Finally, Chardan Capital reissued a “buy” rating and set a $53.00 price target on shares of uniQure in a research report on Thursday, December 4th.

uniQure Stock Down 1.0%

Shares of uniQure stock opened at $24.56 on Thursday. uniQure has a 12-month low of $7.76 and a 12-month high of $71.50. The firm has a market capitalization of $1.53 billion, a PE ratio of -5.59 and a beta of 0.59. The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 0.23. The stock’s fifty day moving average is $32.98 and its 200-day moving average is $27.06.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.53). The company had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $4.46 million. uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%. Equities analysts anticipate that uniQure will post -3.75 earnings per share for the current year.

Insider Transactions at uniQure

In other news, Director Jack Kaye sold 38,810 shares of the stock in a transaction that occurred on Tuesday, November 4th. The shares were sold at an average price of $30.34, for a total value of $1,177,495.40. Following the completion of the sale, the director directly owned 20,439 shares of the company’s stock, valued at $620,119.26. This represents a 65.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Robert Gut sold 31,434 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $27.26, for a total transaction of $856,890.84. Following the transaction, the director directly owned 40,145 shares in the company, valued at $1,094,352.70. The trade was a 43.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 4.79% of the stock is owned by corporate insiders.

Institutional Trading of uniQure

Hedge funds and other institutional investors have recently modified their holdings of the company. Vestal Point Capital LP grew its stake in uniQure by 58.4% in the first quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company’s stock valued at $50,801,000 after purchasing an additional 1,767,572 shares in the last quarter. Avoro Capital Advisors LLC grew its stake in shares of uniQure by 22.6% in the 3rd quarter. Avoro Capital Advisors LLC now owns 4,444,444 shares of the biotechnology company’s stock valued at $259,422,000 after buying an additional 819,444 shares in the last quarter. Aberdeen Group plc grew its stake in shares of uniQure by 6.9% in the 3rd quarter. Aberdeen Group plc now owns 2,939,743 shares of the biotechnology company’s stock valued at $171,593,000 after buying an additional 189,029 shares in the last quarter. Nantahala Capital Management LLC increased its holdings in uniQure by 3.8% in the first quarter. Nantahala Capital Management LLC now owns 2,755,962 shares of the biotechnology company’s stock worth $29,213,000 after buying an additional 101,598 shares during the last quarter. Finally, Jefferies Financial Group Inc. bought a new position in uniQure during the second quarter valued at approximately $29,217,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.